Navigation Links
CryoLife to Present at 23rd Annual Piper Jaffray Health Care Conference
Date:11/21/2011

ATLANTA, Nov. 21, 2011 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that it will participate in the upcoming 23rd Annual Piper Jaffray Health Care Conference on Wednesday, November 30, 2011 at The New York Palace Hotel in New York City.

Steven G. Anderson, president and chief executive officer of CryoLife, Inc., is scheduled to present at 4:00 p.m. Eastern Time.  

CryoLife's live presentation may be accessed through its Web site, www.cryolife.com, on the Investor Relations page.  An archived copy of the presentation will be available for 90 days on the same Web site.

About CryoLifeFounded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S. and Canada. CryoLife's CryoValve® SG pulmonary heart valve, processed using CryoLife's proprietary SynerGraft® technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed, or malfunctioning native or prosthetic pulmonary valves.  CryoLife's CryoPatch® SG pulmonary cardiac patch has FDA 510(k) clearance for the repair or reconstruction of the right ventricular outflow tract (RVOT), which is a surgery commonly performed in children with congenital heart defects, such as Tetralogy of Fallot, Truncus Arteriosus, and Pulmonary Atresia. CryoPatch SG is distributed in three anatomic configurations: pulmonary hemi-artery, pulmonary trunk, and pulmonary branch.  CryoLife's BioGlue® Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels.  BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair and was recently approved in Japan for use in the repair of aortic dissections.  CryoLife, through its subsidiary Cardiogenesis Corporation, specializes in the treatment of cardiovascular disease and the sale of devices that treat severe angina.  Its market leading FDA-approved Holmium: YAG laser system and single use fiber-optic delivery systems are used to perform a surgical procedure known as Transmyocardial Revascularization (TMR).  CryoLife distributes PerClot®, an absorbable powder hemostat, in the European Community.  CryoLife's BioFoam™ Surgical Matrix is CE marked in the European Community for use as an adjunct in the sealing of abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by ligature or other conventional methods is ineffective or impractical.  

For additional information about the company, visit CryoLife's Web site: http://www.cryolife.com.Contacts:CryoLife
D. Ashley Lee
Executive Vice President, Chief Financial Officer and Chief Operating Officer
Phone: 770-419-3355

The Ruth Group
Nick Laudico / Zack Kubow
646-536-7030 / 7020
nlaudico@theruthgroup.com
zkubow@theruthgroup.com
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CryoLife Reports Financial Results for the Third Quarter and First Nine Months of 2011
2. CryoLife Initiates Enrollment in U.S. Clinical Trial for BioFoam®
3. CryoLife Announces Release Date and Teleconference Call Details for 2011 Third Quarter Financial Results
4. CryoLife Provides Update on ValveXchange®, Inc. Investment
5. CryoLife Reports Record Revenues for the Second Quarter and First Six Months of 2011
6. CryoLife Announces Release Date and Teleconference Call Details for 2011 Second Quarter Financial Results
7. CryoLife Makes Equity Investment in ValveXchange® Inc.
8. CryoLife Announces Completion of Acquisition of Cardiogenesis
9. CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation
10. CryoLife Completes Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation
11. CryoLife Posts Record Quarterly Revenues of $30.2 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 4, 2016 ... across 154 pages, profiling 09 key companies and ... a professional and in-depth study on the current ... basic overview of the industry including definitions, classifications, ... market analysis is provided for the international market ...
(Date:5/3/2016)... , May 3, 2016  Axiogenesis has acquired a major investment from Sino-German High-Tech Fund to further expand ... Photo - http://photos.prnewswire.com/prnh/20160503/362921 ... ... ... ...
(Date:5/3/2016)... , May 3, 2016   BIOTRONIK ... technology, today announced Food and Drug Administration (FDA) ... defibrillator that provides heart failure patients with access ... devices also have remote monitoring with daily automatic ... the heart rate in response to physiological demands. ...
Breaking Medicine Technology:
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... among Pittsburgh-area schoolchildren has found that more than 40 percent of participating fifth-grade ... MD , Director of Allergy and Asthma Clinical Research in the Division of ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... Dr. Benjamin ... in non-surgical hair loss treatment. Dr. Stong is double board certified and the ... for the treatment of hair loss. Non-surgical therapies such as stem cells can ...
(Date:5/5/2016)... ... May 05, 2016 , ... The 2016 Nike Soccer Camp will be directed ... university coaching staff. Together they bring their winning Vandals coaching philosophy to young athletes. ... ages 5-13, and high school players. Session dates are as follows: , Youth Day ...
(Date:5/5/2016)... ... May 05, 2016 , ... When stiff and achy joints ... the pain that’s a common osteoarthritis (OA) symptom. Yet, numerous clinical studies point ... arthritis. , “Physical therapy exercises are commonly prescribed to individuals with osteoarthritis ...
(Date:5/5/2016)... ... ... Lung Institute will celebrate its three-year anniversary on May 14 by giving away ... month of May. To date, the Lung Institute has treated over 2,000 people at their ... testament to the success of this treatment and to the patients who refuse to give ...
Breaking Medicine News(10 mins):